Literature DB >> 2894613

Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma.

B R Seizinger1, G A Rouleau, L J Ozelius, A H Lane, G E Farmer, J M Lamiell, J Haines, J W Yuen, D Collins, D Majoor-Krakauer.   

Abstract

Von Hippel-Lindau disease (VHL) is an autosomal dominant disorder with inherited susceptibility to various forms of cancer, including hemangioblastomas of the central nervous system, phaeochromocytomas, pancreatic malignancies, and renal cell carcinomas. Renal cell carcinomas constitute a particularly frequent cause of death in this disorder, occurring as bilateral and multifocal tumours, and presenting at an earlier age than in sporadic, non-familial cases of this tumour type. We report here that the VHL gene is linked to the locus encoding the human homologoue of the RAF1 oncogene, which maps to chromosome 3p25 (ref. 4). Crossovers with the VHL locus suggest that the defect responsible for the VHL phenotype is not a mutation in the RAF1 gene itself. An alternative or prior event to oncogene activation in tumour formation may be the inactivation of a putative 'tumour suppressor' which can be associated with both the inherited and sporadic forms of the cancer. Sporadic renal cell carcinomas have previously been associated with the loss of regions on chromosome 3p (refs 5, 6). Consequently, sporadic and VHL-associated forms of renal cell carcinoma might both result from alterations causing loss of function of the same 'tumour suppressor' gene on this chromosome.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894613     DOI: 10.1038/332268a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  111 in total

Review 1.  HIF hydroxylation and the mammalian oxygen-sensing pathway.

Authors:  Michal Safran; William G Kaelin
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

Review 2.  Von Hippel-Lindau disease.

Authors:  E R Maher; A T Moore
Journal:  Br J Ophthalmol       Date:  1992-12       Impact factor: 4.638

3.  Construction of a human chromosome 3 specific NotI linking library using a novel cloning procedure.

Authors:  E R Zabarovsky; F Boldog; T Thompson; D Scanlon; G Winberg; Z Marcsek; R Erlandsson; E J Stanbridge; G Klein; J Sümegi
Journal:  Nucleic Acids Res       Date:  1990-11-11       Impact factor: 16.971

Review 4.  Application of molecular cytogenetic techniques to the evaluation of renal parenchymal tumors.

Authors:  G Kovacs
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

5.  Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas.

Authors:  A O Vortmeyer; I A Lubensky; F Fogt; W M Linehan; U Khettry; Z Zhuang
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

6.  Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents.

Authors:  M T Sgambati; C Stolle; P L Choyke; M M Walther; B Zbar; W M Linehan; G M Glenn
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

7.  Ophthalmic pathology of genotypically confirmed von Hippel Lindau disease type 1.

Authors:  C M Knapp; G Woodruff; F Roberts
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

8.  Molecular pathology and CXCR4 expression in surgically excised retinal hemangioblastomas associated with von Hippel-Lindau disease.

Authors:  Xiaoling Liang; Defen Shen; Yongsheng Huang; Chunyue Yin; Christine M Bojanowski; Zhengping Zhuang; Chi-Chao Chan
Journal:  Ophthalmology       Date:  2006-10-27       Impact factor: 12.079

9.  Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma.

Authors:  E R Maher; J R Yates; M A Ferguson-Smith
Journal:  J Med Genet       Date:  1990-05       Impact factor: 6.318

10.  Solid haemangioblastomas of the CNS: a review of 17 consecutive cases.

Authors:  Jens Rachinger; Rolf Buslei; Julian Prell; Christian Strauss
Journal:  Neurosurg Rev       Date:  2008-09-20       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.